LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications , today announced that an abstract reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming CHEST Annual Meeting, to be held in Nashville, Tennessee from October 16-19, 2022.
Poster presentation details:
Title: Prior specialist consultations and treatments in a refractory chronic cough population enrolled in a phase 2b study of the P2X3 antagonist BLU-5937
Session: Signs and symptoms of chest disease
Date/Time: Tuesday, October 18th2022, 2:30-3:30 pm ET/1:30-2:30 pm CT
CHEST has announced that the abstract will be made available today on the CHEST® journal website here. After the conference, the presentation materials will be available in the “Scientific Publications” section of the BELLUS Health website at www.bellushealth.com.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of RCC and other cough hypersensitivity indications. The company’s product candidate, BLU-5937, has successfully completed a Phase 2b trial at RCC. BELLUS Health is preparing to launch its CALM Phase 3 program in the fourth quarter of 2022.
A chronic cough is a cough that lasts more than eight weeks. When the cause of chronic cough cannot be identified or the cough persists despite treatment of all identified associated causes, the condition is referred to as RCC. It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant negative physical, social and psychological effects on health and quality of life. Currently, there is no specific therapy approved for RCC outside of Japan and Switzerland, and treatment options are limited.
The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitivity conditions.
Forward-looking statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable as of the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities laws and regulations, the Reform Act of the US Private Securities Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are often, but not always, identified by words such as “expects,” “anticipates,” “believes,” “aims,” ”estimates,” “potential,” “possible,” “projects,” “plans.” . ,” and similar expressions. Such statements, based on management’s current expectations, inherently involve numerous significant risks, uncertainties and assumptions, both known and unknown, many of which are beyond BELLUS Health’s control. Such statements include, but are not limited to, the potential of BLU-5937 to successfully treat RCC and other hypersensitivity-related disorders and to benefit such patients, BELLUS Health’s expectations regarding its preclinical studies and trials clinical trials, the timing and outcome of interactions with regulatory agencies, the potential activity and tolerability profile, selectivity, potency and other characteristics of BLU-5937, and the potential applicability of BLU-5937 and BELLUS Health’s P2X3 platform for the treatment of disorders of others. Risk factors that could affect BELLUS Health’s future results include, but are not limited to: the benefits and impact on the label of its enrichment strategy, estimates and forecasts regarding the size and opportunity of the addressable RCC market for BLU -5937, the ability to expand and develop its project, the ability to obtain adequate financing, the ability of BELLUS Health to maintain its intellectual property rights and to obtain adequate protection of future products through a proprietary such intellectual property, the impact of general economic conditions, general conditions in the pharmaceutical industry, the impact of the ongoing COVID-19 pandemic on BELLUS Health’s operations, plans and prospects, including the timely initiation and completion of clinical trials or at all; changes in the regulatory environment in the jurisdictions in which BELLUS Health does business, supply chain impacts, peace stock market volatility, cost fluctuations, changes in the competitive environment measures due to consolidation, achievement of anticipated burn rate, achievement of anticipated preclinical studies and clinical trials, support from third parties to conduct preclinical studies and trials clinical trials for BLU-5937 and that the actual results may differ from the final results once they are final and qualitative -Controlled verification of data and analysis has been completed. In addition, the length of BELLUS Health’s product candidate development process and its market size and commercial value depend on a number of factors. In addition, BELLUS Health’s future growth and prospects depend largely on the successful development, patient tolerability, regulatory approval, commercialization and market acceptance of its product candidate BLU-5937 and other products. Accordingly, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. BELLUS Health believes that the expectations represented by the forward-looking statements are reasonable, however there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements contained in this news release. These forward-looking statements speak only as of the date made, and BELLUS Health undertakes no obligation and disclaims any intention to publicly update or revise such statements as a result of any new information, future events, circumstances or otherwise, except as required by applicable law. legislation or regulation. Please see BELLUS Health’s public filings with Canadian securities regulatory authorities, including, but not limited to, its Annual Information Form and the United States Securities and Exchange Commission, including, but not limited to was limited in its Annual Report on Form 40-F to further risk factors that may affect BELLUS Health and its business.
Source: BELLUS Health Inc.
